Atea Pharmaceuticals (AVIR) Net Margin (2021)

Atea Pharmaceuticals (AVIR) recorded quarterly Net Margin of 60.95% in Q4 2021, up 170.93% quarter-over-quarter from 85.93% in Q3 2021.

Atea Pharmaceuticals (AVIR) Net Margin (2021) Analysis & Trends

Atea Pharmaceuticals' Net Margin history runs 1 years deep, the most recent figure standing at 60.95% for Q4 2021.

In Q4 2021, Net Margin changed N/A year-over-year to 60.95%; the TTM figure through Dec 2021 stood at 34.49% (changed N/A YoY), while the FY2021 annual figure was 34.49%, up 5700.0% from the prior year.
Net Margin was 60.95% for Q4 2021 at Atea Pharmaceuticals, up from 85.93% in the prior quarter.
In the past five years, Net Margin ranged from a high of 60.95% in Q4 2021 to a low of 85.93% in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	0.82%
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	34.53%
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Atea Pharmaceuticals	347.28 Mn	347.28 Mn	-	-

Download Data